Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pegozafermin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Participants will receive pegozafermin as per the schedule specified in the protocol in the abdomen. |
| Group B | EXPERIMENTAL | Participants will receive pegozafermin as per the schedule specified in the protocol in the thigh. |
| Group C | EXPERIMENTAL | Participants will receive pegozafermin as per the schedule specified in the protocol in the upper arm. |
| Name | Type | Description |
|---|---|---|
| Pegozafermin | DRUG | Pergozafermin will be administered as specified in the protocol. |
Inclusion Criteria: * Participants with a body mass index (BMI) within the range of 18.5-35.0 kilogram per square meter (kg/m²) * Participants in good health, as determined by medical history, physical examination findings, vital signs, electrocardiogram (ECG), and clinical laboratory tests at scre...
Pegozafermin is an investigational small molecule being developed by Roche Holding AG. It is currently in Phase 1 clinical development and is being studied in healthy volunteers. The single registered trial is designed to assess how the injection site affects the pharmacokinetics of pegozafermin when given as a subcutaneous injection.
Pegozafermin is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor of the Phase 1 program evaluating the drug in healthy volunteers.
Pegozafermin is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The program currently consists of one registered trial in healthy volunteers, and that trial has not yet begun recruiting participants.
Pegozafermin is being studied in one registered clinical trial, NCT07835243, titled A Study to Assess the Effect of Subcutaneous Injection Site on the Pharmacokinetics of Pegozafermin in Healthy Participants. The Phase 1 trial is not yet recruiting and is expected to enroll 105 healthy volunteers aged 18 years and older.
The Phase 1 trial NCT07835243 is a controlled, randomized study of pegozafermin given by subcutaneous injection to healthy volunteers. It is not double blinded. The study is designed to assess the effect of the subcutaneous injection site on the pharmacokinetics of pegozafermin, and it plans to enroll 105 participants.